Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Elevation Oncology logo — We are focused on discovering and developing selective cance...

Elevation Oncology

We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors

Founded 2019 United States Boston, United States 5 employees Acquired Total: $232.95M Biopharma, Biotechnology +3

General Information

Company Name Elevation Oncology
Founded Year 2019
Location United States Boston, United States
Employees 5
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Acquired
Social

BounceWatch is an independent company data service, not affiliated with Elevation Oncology. To contact Elevation Oncology, visit elevationoncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Elevation Oncology compare?

A PDF of Elevation Oncology and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Elevation Oncology soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Elevation Oncology

Elevation Oncology, founded in 2019, is a pioneering oncology company with a focus on discovering and developing selective cancer therapies for patients with various solid tumors and significant unmet medical needs. The company's slogan, "We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors," encapsulates its mission. Elevation Oncology is redefining drug development by identifying innovative, selective cancer therapies that can be tailored to an individual patient’s tumor characteristics. Its lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) engineered to target Claudin 18.2, a clinically validated molecular target. This therapy selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. The company is swiftly moving forward with advancing EO-3021 into clinical trials in the United States, focusing on a range of solid tumor indications. Additionally, Elevation Oncology is exploring new partnerships and business development opportunities to expand its innovative oncology pipeline. As of 08 June 2023, Elevation Oncology secured a significant investment of $50.00M in post-IPO equity financing, indicating growing investor interest and confidence in the company's potential to make an impact in the biopharma, biotechnology, health care, and pharmaceutical industries. Based in the United States, Elevation Oncology stands at the forefront of transformative cancer treatment development, poised to address critical medical needs with its pioneering approach.

Business keywords: oncology research, cancer therapies, solid tumors, antibody drug conjugate, Claudin 18.2, genomic tests, NRG1 fusions, clinical trials, drug development, precision medicine

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition Undisclosed 1
Concentra Biosciences
01 Jun 2025
Post-IPO Equity $50.00M -
01 Jun 2023
Post-IPO Debt $50.00M 1
K2 HealthVentures
K2 HealthVentures
01 Jul 2022
IPO Undisclosed -
01 Jun 2021
Series B $65.00M 11
Qiming Venture Partners USA Vivo Capital Aisling Capital
Qiming Venture Partners USA, Vivo Capital +9
01 Nov 2020
Series A $32.50M 5
Qiming Venture Partners USA Aisling Capital BVF Partners
Qiming Venture Partners USA, Aisling Capital +3
01 Jul 2020
Series A $30.00M 5
Qiming Venture Partners USA Aisling Capital BVF Partners
Qiming Venture Partners USA, Aisling Capital +3
01 Jan 2020
Seed $5.45M -
01 Jul 2017

Elevation Oncology Alternatives & Competitors

View All Alternatives
Elevation Oncology vs
Tagworks Pharmaceuticals
Tagworks Pharmaceuticals The Netherlands

Pioneer of Click-to-Release chemistry; designing more effective and safer systemic therapies

Series A
47 employees
Biotechnology, Health Care
Compare Elevation Oncology vs Tagworks Pharmaceuticals
Elevation Oncology vs
Tarveda Therapeutics
Tarveda Therapeutics United States

To discover, develop and commercialize a new class of potent and selective precision oncology medici...

5 employees
Biotechnology, Health Care
Elevation Oncology vs
I-Mab Biopharma
I-Mab Biopharma United States

Transforming Potential into Reality.

Post-IPO Equity
100 employees
Biotechnology, Pharmaceutical
Compare Elevation Oncology vs I-Mab Biopharma
View all alternatives

FAQ About Elevation Oncology

We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors
Elevation Oncology was founded in 2019.
Elevation Oncology is headquartered in Boston, United States.
Elevation Oncology operates in Biopharma, Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on oncology research, cancer therapies, solid tumors and antibody drug conjugate.
Elevation Oncology has approximately 5 employees.
Elevation Oncology has completed 8 funding rounds, raising a total of $232.95M. The latest funding stage is Acquired.
Top alternatives and competitors to Elevation Oncology include Tagworks Pharmaceuticals, Tarveda Therapeutics, I-Mab Biopharma, Prescient Therapeutics, DEM Biopharma, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elevation Oncology and Tagworks Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Elevation Oncology, https://bouncewatch.com/company/elevation-oncology, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout